Evidence | Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Evidence

Supporting evidence

Evidence review
A1: Symptoms and signs associated with bacterial meningitis (PDF 2.22 MB)

Published:

19 March 2024
A2: Risk factors associated with bacterial meningitis (PDF 804 KB)

Published:

19 March 2024
A3: Symptoms and signs associated with meningococcal disease (PDF 1.52 MB)

Published:

19 March 2024
A4: Risk factors associated with meningococcal disease (PDF 941 KB)

Published:

19 March 2024
B1: Investigating and diagnosing suspected bacterial meningitis with blood and urine investigations (PDF 1.68 MB)

Published:

19 March 2024
B2: Investigating and diagnosing suspected meningococcal disease with blood and urine investigations (PDF 1.07 MB)

Published:

19 March 2024
B3: Investigating and diagnosing suspected bacterial meningitis with cerebrospinal fluid parameters (PDF 4.47 MB)

Published:

19 March 2024
B4: Factors associated with brain herniation (PDF 577 KB)

Published:

19 March 2024
B5: Role of neuroimaging prior to lumbar puncture (PDF 668 KB)

Published:

19 March 2024
C1: Timing of antibiotics for bacterial meningitis (PDF 849 KB)

Published:

19 March 2024
C2: Timing of antibiotics for meningococcal disease (PDF 876 KB)

Published:

19 March 2024
D1: Antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in younger infants (PDF 717 KB)

Published:

19 March 2024
D2: Antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in older infants and children (PDF 1.26 MB)

Published:

19 March 2024
D3: Antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in adults (PDF 874 KB)

Published:

19 March 2024
E1: Antibiotics for bacterial meningitis caused by Streptococcus pneumoniae (PDF 707 KB)

Published:

19 March 2024
E2: Antibiotics for bacterial meningitis caused by Haemophilus influenzae (PDF 750 KB)

Published:

19 March 2024
E3: Antibiotics for bacterial meningitis caused by Group B streptococcus (PDF 619 KB)

Published:

19 March 2024
E4: Antibiotics for bacterial meningitis caused by Gram-negative bacilli (PDF 694 KB)

Published:

19 March 2024
E5: Antibiotics for bacterial meningitis caused by Listeria monocytogenes (PDF 596 KB)

Published:

19 March 2024
E6: Antibiotics for bacterial meningitis caused by Neisseria meningitidis (PDF 805 KB)

Published:

19 March 2024
F: Antibiotics for meningococcal disease (PDF 646 KB)

Published:

19 March 2024
G1: Fluid restriction in bacterial meningitis (PDF 573 KB)

Published:

19 March 2024
G2: Osmotic agents in bacterial meningitis (PDF 654 KB)

Published:

19 March 2024
G3: Intracranial pressure monitoring in bacterial meningitis (PDF 614 KB)

Published:

19 March 2024
G4: Corticosteroids for treatment of bacterial meningitis (PDF 990 KB)

Published:

19 March 2024
H: Corticosteroids in meningococcal disease (PDF 659 KB)

Published:

19 March 2024
I1: Long-term complications and follow-up for bacterial meningitis (PDF 2.13 MB)

Published:

19 March 2024
I2: Long-term complications and follow-up for meningococcal disease (PDF 1.12 MB)

Published:

19 March 2024
J1: Factors associated with recurrent bacterial meningitis (PDF 959 KB)

Published:

19 March 2024
J2: Factors associated with recurrent meningococcal disease (PDF 645 KB)

Published:

19 March 2024
K1: Information for suspected bacterial meningitis or meningococcal disease (PDF 1.18 MB)

Published:

19 March 2024
K2: Support for suspected bacterial meningitis or meningococcal disease (PDF 826 KB)

Published:

19 March 2024
K3: Information for confirmed bacterial meningitis or meningococcal disease (PDF 1.02 MB)

Published:

19 March 2024
K4: Support for confirmed bacterial meningitis or meningococcal disease (PDF 1000 KB)

Published:

19 March 2024
Evidence reviews – March 2024
Other supporting evidence
Methods (PDF 413 KB)

Published:

19 March 2024